According to the latest sales data provided by the consulting company GlobalData, in 2007, Novartis has surpassed Pfizer as the No. 1 pharmaceutical giant due to the expiration of patents and the renewal of heavy drugs. Previously, Pfizer had already occupied the top spot for many years.
2014 global prescription drug sales TOP25 pharmaceutical giant, Novartis won
In recent years, large pharmaceutical companies have generally faced patent cliff problems. For example, Pfizer's patents for Integration have expired. Although the sales champions have remained in the previous two years, sales have continued to decline (Lipto has sold $13 billion annually). In 2014, sales were only $2.8 billion). Other companies ranked in the top ten have faced the same problem in the past two years. Sales performance has been slow in recent years, and even sustained negative growth. This has also forced these large pharmaceutical companies to find new breakthroughs, including business restructuring and increased research and development of new drugs.
Novartis is far beyond Pfizer's strategic restructuring and restructuring. In April 2014, Novartis, GlaxoSmithKline (GSK) and Lilly came to an “asset exchangeâ€. As can be seen from this series of transactions, these companies are focusing on areas of strength in areas that they are not good at. In this transaction, Novartis sold a relatively low-margin vaccine business (to GSK) and animal health business (to Lilly); at the same time, Novartis acquired GSK's oncology business (including R&D, product intellectual property and market) ). Novartis originally had a very strong strength in the field of cancer. The acquisition acquired Votrient (pazopanib) and other drugs to further strengthen its strength in the field of cancer. In addition, Novartis' OTC business will form a joint venture with GSK's Consumer Business consumer business. The two parties introduced their respective consumer health products, including OTC drugs and daily consumer products, to the new company. Among them, Novartis accounted for 36.5% of the shares, and GSK accounted for 63.5%. After the merger of Novartis and GSK's consumer health products, sales are expected to reach US$6.5 billion, ranking second in the world, and 9.8 billion US dollars for Johnson & Johnson. This merger strengthens Novartis's advantages in prescription drugs and brings a lot of direct income. In addition to this asset exchange, Novartis also sold its flu vaccine business to CSL. As new drug research and development becomes more and more difficult, the current way of focusing on advantages helps companies to invest in areas they are good at.
In terms of drug research and development, Novartis's R&D budget for 2014 reached $9.9 billion. In terms of drug efficiency research and development, Novartis also adopted the kill the losers strategy, decisively abandon those zombie projects, sell them or simply give up, avoiding wasting time and cost, saving time and cost can be used to support the success rate. High or more promising projects. In the case of Novartis's vaccine business, although most of the vaccine business has been sold, some vaccines are still retained. The company's vaccine, Bexsero, was approved by the FDA in January to prevent meningitis caused by serogroup B meningococcus, which was once approved for breakthrough treatment.
For the patent cliff problem of heavy drugs, Novartis is more of a strategy to increase research and development. Taking valsartan as an example, Novartis has begun research and development of a new generation of antihypertensive drugs before the expiration of the patent, and successfully developed LCZ-696. LCZ-696, a combination of valsartan and sacubitril, may also be used to treat heart failure, further expanding the market for indications. Reuters expects the drug to reach $3.7 billion in sales in 2019.
At present, Novartis has a number of potential heavy products, including Jakavi (ruxolitinib), Cosentyx (secukinumab), Ultibro Breezhaler, Farydak (panobinostat, LBH589), Gilenya and so on.
Jakavi is an oral JAK kinase inhibitor approved by the FDA for use in bone fibrosis and polycythemia vera (PV) indications. The drug has recently been approved by the European Union and can be used to treat polycythemia vera. There is no doubt that the relevant person predicts that the drug will become a heavy drug.
Cosentyx is currently the world's first approved monoclonal antibody to interleukin-17 (IL-17), which was approved by both the FDA and the European Union earlier this year. Clinical trial results indicate that Cosentyx is superior to Pedestrian's Stelara and Amgen's biotherapetic Enbrel for Psoriasis. Although there are competitors like Otezla (celegene), Cosentyx's good clinical trial results will provide a strong guarantee for its entry into the European and American markets. Experts expect their annual sales to reach $1 billion.
Ultibro Breezhaler (glycopyrronium/indacaterol, Glon/indazol maleate) is a dual-mode bronchodilator administered by Breezhaler single-dose dry powder inhaler. The drug has been approved in more than 30 countries to relieve symptoms in patients with COPD. The industry predicts that the drug may become an important boost for Novartis to defeat GlaxoSmithKline and seize the COPD market.
Farydak (panobinostat, LBH589) is a broad-spectrum HDAC inhibitor that was approved by the FDA in February this year and is used in combination with Velcade (bortezomib, bortezomib) and dexamethasone for the treatment of at least two treatment regimens. Multiple myeloma patients.
Gilenya (fingolimod, fingolimod) is an oral drug for multiple sclerosis (MS). The drug was approved by the FDA in 2010 and was approved by the European Union in 2011.
In the second half of this year, Novartis' cancer treatments LDE225, QVA149, NVA237 and LCZ696 are expected to be approved by the FDA.
In addition to these products, Novartis has also been active in the field of cancer immunotherapy, which has recently received much attention. In the CAR-T field, Novartis has been at the forefront, and the company's CAR-T cancer treatment drug CTL019 has demonstrated excellent results in clinical trials of cancers such as lymphoma and acute lymphoblastic leukemia. At the same time, Novartis does not give up the combination of CAR-T and other technologies. For example, in January this year, Novartis invested in Intellia Therapeutics, a new star company specializing in CRISPR technology, and hopes to apply its CRISPR to CAR-T. In addition, the recent CART-meso new therapy developed by Novartis Investment Penn has also achieved success in Phase I clinical practice. Novartis announced in early April that it will collaborate with Aduro Biotech to develop its cyclic dinucleoside interferon gene activator (STING) ligand. STING is a signaling protein that detects intracellular exogenous nucleosides and induces the synthesis of interferons to activate the immune system. It is a novel immunotherapy.
In addition to new drug development, Novartis has also achieved success in the biosimilars market. At the beginning of this year, Novartis Zarzio received the FDA's affirmation that the drug is a biosimilar of Amgen's biopharmaceutical Neupogen. Neupogen can prevent infection in patients after chemotherapy. The drug contributed $1.2 billion in sales to Amgen in 2014. Zarzio has a clear price advantage, and it is likely to seize a small market share and bring new benefits to Novartis.
ZHANGJIAGANG DINSHENGLIN TRADING CO.,LTD , https://www.dslhouse.com